Guoxin J. Ren
No. 639 Zhizaoju Rd
Shanghai, China
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
CD266+ myofibroblasts mediate resistance to immunochemotherapy through ECM stiffness in head and neck squamous cell carcinoma.
Journal: Cancer immunology research
Published: November 04, 2025
Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma.
Journal: Cancer treatment reviews
Published: September 08, 2025
Pembrolizumab With Anlotinib in Advanced Oral Mucosal Melanoma: A Retrospective Trial.
Journal: Oral diseases
Published: August 06, 2025
Neoadjuvant Pembrolizumab Combined with Chemotherapy for Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinomas: A Single-center Retrospective Study.
Journal: Journal of Cancer
Published: July 22, 2025
Study on the correlation between the expression of Porphyromonas gingivalis, tumor-associated macrophages and the clinical prognosis of oral squamous cell carcinoma
Journal: Shanghai kou qiang yi xue = Shanghai journal of stomatology
Published: June 23, 2025
IL-4-STAT6-induced high Siglec-G/10 expression aggravates the severe immune suppressive tumor microenvironment and impedes the efficacy of immunotherapy in head and neck squamous cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: May 19, 2025
Real-World Study of Later-Line Anlotinib in R/M Head and Neck Squamous Cell Carcinoma.
Journal: Oral diseases
Published: December 06, 2024
Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 24, 2024
Chinese Expert Consensus on Management of Betel-Chewing-Related Oral Squamous Cell Carcinoma.
Journal: Oral diseases
Published: June 07, 2024
The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a single center, real world study in China.
Journal: Frontiers in oncology
Published: December 23, 2023
The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma.
Journal: Journal of Cancer
Published: November 28, 2023
Last Updated: 09/26/2026